The Institute for Clinical and Economic Review (ICER) has published its final report on Spravato (esketamine ... and have large negative effects on patient quality of life, so new therapies ...

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 ...

Spravato was first approved for use in 2019 to treat people with major depressive disorder who did not respond to at least ...

J&J's Spravato was FDA-approved in January as the ... The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no ...

The approval, announced today, follows a Priority Review by the FDA and is based ... The study showed that patients treated with SPRAVATO® alone experienced relief from depressive symptoms ...

Our treatments are effective and powerful, allowing people to feel better faster with long-lasting relief: 74% of patients report improvement in anxiety, 86% of Spravato patients report ...

Just building on everything that J&J has established with Spravato, but making it much more convenient for the patient, much more convenient for the provider. JN: Maybe just a a little more ...

However, it may cover Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and can help manage treatment-resistant depression. Despite not yet having FDA ...

Accepting New Spravato Patients- Katie Stanford is a board certified Psychiatric/Mental Health Nurse Practitioner who works with adults (18+) and provides care for patients who struggle with ...